This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Alexenko A.P., Ealy A.D., Roberts R.M.: The cross-species antiviral activities of different IFN-tau subtypes on bovine, murine, and human cells: contradictory evidence for therapeutic potential. J Interferon Cytokine Res 1999, 19, 1335–1341, doi: 10.1089/107999099312795.AlexenkoA.P.EalyA.D.RobertsR.M.The cross-species antiviral activities of different IFN-tau subtypes on bovine, murine, and human cells: contradictory evidence for therapeutic potential1999191335134110.1089/107999099312795Open DOISearch in Google Scholar
Armstrong J.A.: Cytopathic effect inhibition assay for interferon: microculture plate assay. Methods Enzymol 1981, 78, 381–387, doi: 10.1016/0076-6879(81)78145-x.ArmstrongJ.A.Cytopathic effect inhibition assay for interferon: microculture plate assay19817838138710.1016/0076-6879(81)78145-xOpen DOISearch in Google Scholar
Commission of Chinese Veterinary Pharmacopoeia:. Veterinary Pharmacopeia of the People’s Republic of China, 2010 edition. China Agriculture Press, Beijing. 2010, Part I, Appendix 26–130.China Agriculture PressBeijing2010Part I, Appendix26–130Search in Google Scholar
Demmers K.J., Derecka K., Flint A.: Trophoblast interferon and pregnancy. Reproduction 2001, 121, 41–49, doi: 10.1530/rep.0.1210041.DemmersK.J.DereckaK.FlintA.Trophoblast interferon and pregnancy2001121414910.1530/rep.0.1210041Open DOISearch in Google Scholar
Isaacs A., Lindenmann J.: Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957, 147, 258–267, doi: 10.1098/rspb.1957.0048.IsaacsA.LindenmannJ.Virus interference195714725826710.1098/rspb.1957.0048Open DOISearch in Google Scholar
Jeannin P., Duluc D., Delneste Y.: IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-gamma. Immunother 2011, 3, 23–26, doi: 10.2217/imt.11.30.JeanninP.DulucD.DelnesteY.IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-gamma20113232610.2217/imt.11.30Open DOISearch in Google Scholar
Johnson J.A., Hochkeppel H.K., Gangemi J.D.: IFN-tau exhibits potent suppression of human papillomavirus E6/E7 oncoprotein expression. J Interferon Cytokine Res 1999, 19, 1107–1116.JohnsonJ.A.HochkeppelH.K.GangemiJ.D.IFN-tau exhibits potent suppression of human papillomavirus E6/E7 oncoprotein expression1999191107111610.1089/107999099313046Search in Google Scholar
Juste R.A., Ott T.L., Kwang J., Bazer F.W., de la Concha-Bermejillo A.: Effects of recombinant ovine interferon-tau on ovine lentivirus replication and progression of disease. J Gen Virol 2000, 81, 525–532, doi: 10.1099/0022-1317-81-2-525.JusteR.A.OttT.L.KwangJ.BazerF.W.de laConcha-Bermejillo A.Effects of recombinant ovine interferon-tau on ovine lentivirus replication and progression of disease20008152553210.1099/0022-1317-81-2-525Open DOISearch in Google Scholar
Khan O.A., Jiang H., Subramanian P.S., Johnson H.M., Dhib-Jalbut S.S.: Immunomodulating functions of recombinant ovine interferon tau: potential for therapy in multiple sclerosis and autoimmune disorders. Mult Scler 1998, 4, 63–69, doi: 10.1177/135245859800400204.KhanO.A.JiangH.SubramanianP.S.JohnsonH.M.Dhib-JalbutS.S.Immunomodulating functions of recombinant ovine interferon tau: potential for therapy in multiple sclerosis and autoimmune disorders19984636910.1177/135245859800400204Open DOISearch in Google Scholar
Kruger N.J.: The Bradford method for protein quantitation. In: Basic Protein and Peptide Protocols, part of Methods in Molecular Biology vol. 32, edited by J.M. Walker, Humana, Totowa, NJ, 1994, pp. 9–15, doi: 10.1385/0-89603-268-X:9.KrugerN.J.Humana, Totowa, NJ1994pp91510.1385/0-89603-268-X:9Open DOISearch in Google Scholar
Martal J.L., Chêne N.M., Huynh L.P., L’Haridon R.M., Reinaud P.B., Guillomot M.W., Charlier M.A., Charpigny S.Y.: IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie 1998, 80, 755–777, doi: 10.1016/s0300-9084(99)80029-7.MartalJ.L.ChêneN.M.HuynhL.P.L’HaridonR.M.ReinaudP.B.GuillomotM.W.CharlierM.A.CharpignyS.Y.IFN-tau: a novel subtype I IFN119988075577710.1016/s0300-9084(99)80029-7Open DOISearch in Google Scholar
Ott T.L., Van Heeke G., Johnson H.M., Bazer F.W.: Cloning and expression in Saccharomyces cerevisiae of a synthetic gene for the type-I trophoblast interferon ovine trophoblast protein-1: purification and antiviral activity. J Interferon Res 1991, 11, 357–364, doi: 10.1089/jir.1991.11.357.OttT.L.VanHeeke G.JohnsonH.M.BazerF.W.Cloning and expression in Saccharomyces cerevisiae of a synthetic gene for the type-I trophoblast interferon ovine trophoblast protein-1: purification and antiviral activity19911135736410.1089/jir.1991.11.3571800584Open DOISearch in Google Scholar
Pestka S., Krause C.D., Walter M.R.: Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004, 202, 8–32, doi: 10.1111/j.0105-2896.2004.00204.x.PestkaS.KrauseC.D.WalterM.R.Interferons, interferon-like cytokines, and their receptors200420283210.1111/j.0105-2896.2004.00204.x15546383Open DOISearch in Google Scholar
Pitha P.M., Kunzi M.S.: Type I interferon: The ever unfolding story. Curr Top Microbiol 2007, 316, 41–70, doi: 10.1007/978-3540-71329-6_4.PithaP.M.KunziM.S.Type I interferon: The ever unfolding story2007316417010.1007/978-3540-71329-6_4Open DOISearch in Google Scholar
Pontzer C.H., Yamamoto J.K., Bazer F.W., Ott T.L., Johnson H.M.: Potent anti-feline immunodeficiency virus and anti-human immunodeficiency virus effect of IFN-tau. J Immunol 1997, 158, 4351–4357.PontzerC.H.YamamotoJ.K.BazerF.W.OttT.L.JohnsonH.M.Potent anti-feline immunodeficiency virus and anti-human immunodeficiency virus effect of IFN-tau19971584351435710.4049/jimmunol.158.9.4351Search in Google Scholar
Reed L.J., Muench H.: A simple method of estimating 50 percent end points. Am J Hyg 1938, 27, 493–497, doi: 10.1093/oxfordjournals.aje.a118408.ReedL.J.MuenchH.A simple method of estimating 50 percent end points19382749349710.1093/oxfordjournals.aje.a118408Open DOISearch in Google Scholar
Rogez C., Martin M., Dereuddre-Bosquet N., Martal J., Dormont D., Clayette P.: Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and beta-chemokines. J Virol 2003, 77, 12914–12920, doi: 10.1128/JVI.77.23.12914-12920.2003.RogezC.MartinM.Dereuddre-BosquetN.MartalJ.DormontD.ClayetteP.Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and beta-chemokines200377129141292010.1128/JVI.77.23.12914-12920.200326257014610214Open DOISearch in Google Scholar
Rubinstein S., Familletti P.C., Pestka S.: Convenient assay for interferons. J Virol 1981, 37, 755–758, doi: 10.1128/JVI.37.2.755-758.1981.RubinsteinS.FamillettiP.C.PestkaS.Convenient assay for interferons19813775575810.1128/JVI.37.2.755-758.19811710636163873Open DOISearch in Google Scholar
Samuel C.E.: Antiviral actions of interferons. Clin Microbiol Rev 2001, 14, 778–809, doi: 10.1128/CMR.14.4.778-809.2001.SamuelC.E.Antiviral actions of interferons20011477880910.1128/CMR.14.4.778-809.20018900311585785Open DOISearch in Google Scholar
Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., Kuestner R., Garrigues U., Birks C., Roraback J., Ostrander C., Dong D., Shin J., Presnell S., Fox B., Haldeman B., Cooper E., Taft D., Gilbert T., Grant F.J., Tackett M., Krivan W., McKnight G., Clegg C., Foster D., Klucher K.M.: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4, 63–68, doi: 10.1038/ni873.SheppardP.KindsvogelW.XuW.HendersonK.SchlutsmeyerS.WhitmoreT.E.KuestnerR.GarriguesU.BirksC.RorabackJ.OstranderC.DongD.ShinJ.PresnellS.FoxB.HaldemanB.CooperE.TaftD.GilbertT.GrantF.J.TackettM.KrivanW.McKnightG.CleggC.FosterD.KlucherK.M.IL-28, IL-29 and their class II cytokine receptor IL-28R20034636810.1038/ni87312469119Open DOISearch in Google Scholar
Sinha J., Plantz B.A., Zhang W., Gouthro M., Schlegel V., Liu C.P., Meagher M.M.: Improved production of recombinant ovine interferon-tau by mut(+) strain of Pichia pastoris using an optimized methanol feed profile. Biotechnol Prog 2003, 19, 794–802, doi: 10.1021/bp025744q.SinhaJ.PlantzB.A.ZhangW.GouthroM.SchlegelV.LiuC.P.MeagherM.M.Improved production of recombinant ovine interferon-tau by mut(+) strain of Pichia pastoris using an optimized methanol feed profile20031979480210.1021/bp025744q12790641Open DOISearch in Google Scholar
Soos J.M., Johnson H.M.: Interferon-tau: prospects for clinical use in autoimmune disorders. BioDrugs 1999, 11, 125–135, doi: 10.2165/00063030-199911020-00006.SoosJ.M.JohnsonH.M.Interferon-tau: prospects for clinical use in autoimmune disorders19991112513510.2165/00063030-199911020-0000618031121Open DOISearch in Google Scholar
Taylor K.E., Mossman K.L.: Recent advances in understanding viral evasion of type I interferon. Immunology 2013, 138, 190–197, doi: 10.1111/imm.12038.TaylorK.E.MossmanK.L.Recent advances in understanding viral evasion of type I interferon201313819019710.1111/imm.12038357327223173987Open DOISearch in Google Scholar
Tian L., Zhao P., Ma B., Guo G., Sun Y., Xing M-W.: Cloning, expression and antiviral bioactivity of red-crowned crane interferon-alpha. Gene 2014, 544, 49–55, doi: 10.1016/j.gene.2014.04.036.TianL.ZhaoP.MaB.GuoG.SunY.XingM-W.Cloning, expression and antiviral bioactivity of red-crowned crane interferon-alpha2014544495510.1016/j.gene.2014.04.03624768181Open DOISearch in Google Scholar
Todt D., Francois C., Anggakusuma., Behrendt P., Engelmann M., Knegendorf L., Vieyres G., Wedemeyer H., Hartmann R., Pietschmann T., Duverlie G., Steinmann E.: Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrob Agents Chemother 2016, 60, 2132–2139, doi: 10.1128/aac.02427-15.TodtD.FrancoisC.Anggakusuma. BehrendtP.EngelmannM.KnegendorfL.VieyresG.WedemeyerH.HartmannR.PietschmannT.DuverlieG.SteinmannE.Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication2016602132213910.1128/aac.02427-15Open DOISearch in Google Scholar
Usharani J., Park S.Y., Cho E-J., Kim C., Ko Y-J., Tark D., Kim S-M., Park J-H., Lee K-N., Lee M-H., Lee H-S.: Antiviral activity of ovine interferon tau 4 against foot-and-mouth disease virus. Antiviral Res 2017, 143, 134–141, doi: 10.1016/j.antiviral.2017.01.018.UsharaniJ.ParkS.Y.ChoE-J.KimC.KoY-J.TarkD.KimS-M.ParkJ-H.LeeK-N.LeeM-H.LeeH-S.Antiviral activity of ovine interferon tau 4 against foot-and-mouth disease virus201714313414110.1016/j.antiviral.2017.01.01828137623Open DOISearch in Google Scholar
Van Heeke G., Ott T.L., Strauss A., Ammaturo D., Bazer F.W.: High yield expression and secretion of the ovine pregnancy recognition hormone interferon-tau by Pichia pastoris. J Interferon Cytokine Res 1996, 16, 119–126, doi: 10.1089/jir.1996.16.119.VanHeeke G.OttT.L.StraussA.AmmaturoD.BazerF.W.High yield expression and secretion of the ovine pregnancy recognition hormone interferon-tau by Pichia pastoris19961611912610.1089/jir.1996.16.1198742364Open DOISearch in Google Scholar